Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Loi S, Salgado R, Curigliano G, Romero Díaz R, Delaloge S, Rojas García C, Kok M, Saura C, Harbeck N, Mittendorf E, Yardley D, Suárez Zaizar A, Caminos F, Ungureanu A, Reinoso-Toledo J, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu J, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nature Medicine 2025, 31: 433-441. PMID: 39838118, PMCID: PMC11835735, DOI: 10.1038/s41591-024-03414-8.Peer-Reviewed Original ResearchPathological complete responseIncreased pCR ratePhase 3 trialNeoadjuvant chemotherapyBreast cancerER+/HER2- BCNivolumab armPCR rateAnti-programmed death 1 agentsDouble-blind phase 3 trialEndpoint of pathologic complete responseStromal tumor-infiltrating lymphocyte levelsProgrammed death-ligand 1 expressionEstrogen receptor-positive breast cancerLower pathologic complete responseTumor-infiltrating lymphocyte levelsRandomized phase 3 trialReceptor-positive breast cancerHigh riskLigand 1 expressionEstrogen receptor-positivePrimary breast cancerTaxane-based chemotherapyDense lymphocytic infiltrateT cell immunosurveillance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply